Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

• Status: RECRUITING
• Trial end date: 2028-12-30

Summary

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant and CDK4/6 Inhibitors for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.

• Phase: PHASE3

Details

• Lead Sponsor: Celcuity Inc
• Treatments: Fulvestrant; gedatolisib; palbociclib; ribociclib